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ABSTRACT
Introduction The European Reference Network (ERN)
ReCONNET is the ERN aimed at improving the management of
rare and complex connective tissue and musculoskeletal
diseases (rCTDs) across the European Union (EU). In the
mission of ERN ReCONNET, clinical practice guidelines (CPGs)
play a crucial role, representing a valid tool towards the
harmonisation of the management of rCTDs while improving
effectiveness and quality of care delivered to patients.
Methods ERN ReCONNET developed two surveys to map
the adherence to rCTDs CPGs among healthcare providers
and to assess the knowledge and awareness of CPGs for their
diseases among patients, family members and caregivers.
Results The results of the surveys highlighted that
healthcare professionals find it useful to apply CPGs in
clinical practice (93%), while 62% of them experience
difficulties and barriers in the application in their centres.
Healthcare professionals also highlighted the need to
develop CPGs for all rCTDs and to implement the use of the
existing CPGs in clinical practice. On the other hand,
patients, families and caregivers are relatively aware of the
purpose of CPGs (51%) and 62% of them were aware of the
existence of CPGs for their disease. Patient-friendly versions
of CPGs and patients’ lifestyle guidelines should be
systematically developed contributing to the empowerment
of patients in the disease management.
Conclusion ERN ReCONNET is addressing the main issues
identified in the results of the survey, promoting practical
actions for the local adaptation of CPGs across Europe,
improving their routine clinical use and increasing the
awareness on CPGs among rCTDs patients, family members
and caregivers.
INTRODUCTION
Around 5000–8000 rare diseases affect the daily
lives of approximately 30 million people in Eur-
ope. Many of those affected by a rare condition
have limited access to diagnosis and high-
quality treatment. Unfortunately, expertise
and specialist knowledgemay be scarce because
patient numbers are low and improving the
evidence by pooling data can be a challenge.
In order to address these challenges, the
European Commission launched the Eur-
opean Reference Networks (ERNs), virtual
networks involving healthcare providers
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What is already known about this subject?
► Clinical practice guidelines (CPGs) have an important
role in guiding and supporting the decision-making
processes. CPGs cover at present only some rare and
complex connective tissue diseases and more efforts
should be dedicated to the creation of the evidence
needed to support the development of new CPGs.
What does this study add?
► This work provides the perspectives of European
healthcare professionals and patients, family
members and caregivers regarding their
awareness, knowledge and adherence to CPGs.
How might this impact on clinical practice?
► The results of this work highlighted different unmet
needs of the rCTDs communities, including the
adaptation of existing CPGs and the implementation
and development of the evidence needed to produce
new CPGs. Considering that ERN ReCONNET represents
a European infrastructure that can increase the
knowledge and the awareness of existing CPGs, one
of the major added value of the ERN ReCONNET is to
address these unmet needs, providing a framework for
the harmonisation of care in rare and complex
connective tissue diseases in Europe.
Connective tissue diseases
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(HCPs) across Europe. The aim of the ERNs is to tackle
complex or rare diseases and conditions that require
highly specialised treatment and a concentration of knowl-
edge and resources. It is well known that no country alone
has the knowledge and capacity to treat all rare and com-
plex diseases, and exactly for this reason, ERNs were estab-
lished as European infrastructures. ERNs offer, in fact, the
potential to give patients and clinicians across the EU
access to the best expertise and timely exchange of life-
saving knowledge, making knowledge accessible to all
patients, even when living in remote areas.1
Since their launch in 2017 in Vilnius,2 24 ERNs are
currently working on a range of thematic issues, includ-
ing rare connective tissue diseases, bone disorders, child-
hood cancer, metabolic disorders immunodeficiency and
many others.
The ERN ReCONNET3 is 1 of the 24 approved ERNs
aiming at improving themanagement of rare and complex
connective tissue and musculoskeletal diseases (rCTDs)
across the EU. The ERN ReCONNET currently involves
26 full member HCPs from 8 different EU countries:
Belgium, France, Germany, Italy, Netherlands, Portugal,
Romania and Slovenia and 14 affiliated partners (APs)
from additional 11 countries (figure 1). The network, co-
ordinated by the AziendaOspedalieroUniversitaria Pisana
in Italy, covers the following 10 rCTDs: antiphospholipid
syndrome (APS), Ehlers-Danlos syndrome (EDS), idio-
pathic inflammatory myopathies (IIM), IgG4-related dis-
ease (IgG4), mixed connective tissue disease (MCTD),
relapsing polychondritis (RP),€’s syndrome (SS), systemic
lupus erythematosus (SLE), systemic sclerosis (SSc) and
undifferentiated connective tissue disease (UCTD).
Full members HCPs are HCPs that have been identified
as members of the ERN following the process of member-
ship regulated by the Commission Delegated Decision of
10 March 2014 and the Commission Implementing
Figure 1 EU countries involved in the European Reference Network (ERN) ReCONNET.
ERN ReCONNET covers the following countries: Belgium, France, Germany, Italy, The Netherlands, Portugal, Romania and
Slovenia with the HCPs full members, Austria, Croatia, Denmark, Estonia, Hungary, Latvia, Lithuania, Luxembourg, Malta
and Spain with the affiliated partners.
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Decision of 10 March 2014. APs) are HCPs belonging to
member states that do not have representation from a full
member within an ERN; APs are designated by their
member states and can actively participate and contribute
to the ERN activities. Other important components of the
ERN ReCONNET are the external experts (individual
clinician or healthcare professional with an expertise in
the field of rCTDs that are approved by the ERN ReCON-
NET Steering Committee to participate in specific activ-
ities of the ERN) and the members of the ERN
ReCONNET External Scientific Advisory Board (ESAB
—experts considered relevant to the work and mission
of the ERN, such as health economists, methodologists,
policy-makers, etc). In addition, the ERN ReCONNET
involves and engages with patients’ organisations,
thanks to ERN ReCONNET European Patients Advo-
cacy Group (ePAG). The role of ePAGs is particularly
important since they represent the voice of patients in
all the activities of the ERN. All the activities and the
stakeholders involved in the network are co-ordinated
by the ERN ReCONNET Co-ordination Team, which
involves the co-ordinator, project managers and
expert rheumatologist acting also as methodologist.
Clinical practice guidelines (CPGs) serve as an
equaliser in the field of rare diseases. Their applica-
tion can have a high impact on the care of the patient
and their usage highlights the difference between sub-
standard care and patients living longer, healthier
lives with fewer complications.4–9 Guidelines, whether
designed to support correct and early diagnosis or to
guide appropriate care, can serve as a blueprint of
excellence, bringing clinicians and healthcare profes-
sionals closer to the patients on how to treat them,
reflecting the best possible knowledge and generating
the best achievable outcomes. As mentioned in the
Commission Delegated Decision of 10 March 2014,
ERNs should (among other important activities)
develop and implement clinical guidelines supporting
the existing scientific societies in the process. For
these reasons, ERN ReCONNET can play a crucial
role in the implementation of CPGs for rCTDs, pro-
viding valid tools towards the harmonisation of the
management of rCTDs throughout Europe while
improving effectiveness and quality of care delivered
to patients.
In this setting, during the first year of activity of the ERN
ReCONNET, two anonymous surveys were created to
map the adherence to rCTDs CPGs among HCPs mem-
bers and to assess the knowledge and awareness of CPGs
for their diseases among patients/family members/care-
givers. Therefore, we will provide the results of the two
surveys.
METHODS
Of the two surveys developed, the first ‘ERN-ReCONNET
survey on the use of clinical practice guidelines for HCPs’
was dedicated to healthcare professionals and the second
‘ERN ReCONNET survey on clinical practice guidelines
knowledge and awareness in rare and complex connec-
tive tissue disorder patients, families and caregivers’ was
dedicated to patients, caregivers and family members.
ERN-ReCONNET survey on the use of clinical practice
guidelines for HCPs
The survey was developed in English and it was aimed at
assessing the adherence to rCTDs CPGs in European
HCPs who are either members or collaborating with
ERN ReCONNET and at identifying eventual barriers or
limitations that can affect the specialist’s clinical deci-
sions in adopting CPG.
The survey consisted of 19-item questions in English,
subdivided into three sections:
► General sections (demographics, professional charac-
teristics, country of the respondent, etc).
► CPG section.
► Questions concerning potential difficulties/barriers to
the application of CPGs.
The questions of the survey were designed by a group of
methodologists, clinical experts in rCTDs and by the ERN
ReCONNET Co-ordination Team and comprehended
different types of answers (single or multiple-choice,
Likert scale, open answer, etc).The survey was sent to
healthcare professionals from one of the ERN ReCON-
NET full members HCPs or to those who were collaborat-
ing with the ERN as external experts or members of the
ERN ReCONNET ESAB. In total, 110 healthcare profes-
sionals from 38 different European HCPs received the
questionnaire. All the healthcare professionals who
received the questionnaire are involved in reference cen-
tres for rCTDs, specifically, for APS, EDS, IIM, IgG4,
MCTD, RP, SS, SLE, SSc and UCTD.
ERN ReCONNET survey on clinical practice guidelines
knowledge and awareness in rare and complex connective
tissue disorder patients, families and caregivers
Themain purpose was to assess the knowledge and aware-
ness of CPGs. The survey was codesigned in English with
the active participation of the ERN ReCONNET ePAGs
Representatives. Their involvement in the creation of the
questions was particularly important in order to ensure
that the language used was understandable and clear for
most patients, caregivers and family members. The ques-
tions comprehended different types of answers (single or
multiple-choice, Likert scale, open answer, etc).
In order to reach a wider community of patients, care-
givers and family members, a comprehensive list of the
existing European patients’ organisations covering one
or more rCTDs covered by ERN ReCONNET was created
together with the ERN ReCONNET ePAGs representa-
tives. The survey was submitted to a total of 98 rCTDs
patients’ organisations, which disseminated the survey
among their members together with the support of
EURORDIS, the federation of European rare diseases
patients’ organisations, that also contributed to spread-
ing the survey in their communication channels.
Connective tissue diseases
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The survey was developed to explore not only the aware-
ness of CPGs, but also to collect the views of rCTDs
patients, caregivers and family members on their knowl-
edge of the purpose of CPGs, knowledge of the process of
developing CPGs and to gather their perceptions and
expectations. Specifically, the survey was designed to col-
lect the feedback of patients, caregivers and family mem-
bers living with one (or more) of the following diseases:
APS, EDS, IIM, IgG4,MCTD, RP, SS, SLE, SSc andUCTD.
The survey consisted of 21-item questions in English,
subdivided into three sections (general: demographics,
level of education, disease, etc; CPGs knowledge and
awareness; subjective perspective of CPGs).
RESULTS
ERN-ReCONNET survey on the use of CPGs for HCPs
Of the 110 healthcare professionals who received the
survey, 56 completed the questionnaire (response rate
51%)mostly from Italy (36% of the respondents), France
(16%) and the Netherlands (10%). Ninety-one percent
of the respondents belonged to University Hospital and
77% see more than 450 patients per year.
As summarised in table 1, the majority of the respon-
dents (96%) considered that using well-constructed
CPGs would improve patient care and 93% found it
helpful to apply CPGs in clinical practice. With regard
to the existence of CPGs in the area of rCTDs (specifi-
cally, on APS, EDS, IIM, IgG4, MCTD, RP, SS, SLE, SSc
and UCTD), the respondents provided irregular
answers. Some respondents indicated that CPGs in the
area of rCTDs are very few or lacking, while others
reported that CPGs are well constructed and valid.
The variability of the answers for these questions is
related to the fact that for some rCTDs (as in the case
of SLE, SS, SSc and IIM), high-quality CPGs are already
in place, while for other rCTDs (such as RP and IgG4),
CPGs are not yet available since the evidence on these
diseases is still limited. Regarding the use of CPGs in
routine clinical practice, 82% of the respondents use
CPGs always or more than once a week, 16% less than
once a week, while less than 2% never use CPGs when
assessing patients. CPGs are more frequently used in the
diagnosis (82%) and treatment (88%) and slightly less
(67%) in monitoring patients with rCTDs. Sixty-two
percent of the respondents experienced difficulties
and/or barriers to the application of CPG in their cen-
tres and the main reasons were procedures and drug
reimbursement (57%), time limit (49%), local legisla-
tive restrictions (34%), awareness/knowledge (20%)
and poor dissemination of guidelines (17%).
When an open question was asked for a proposal to
increase the adherence to CPGs, the main suggestions
from the respondents were related to the need of
a higher feasibility in clinical practice, in the develop-
ment of actions to modify local legislative restrictions,
and in the creation of easily accessible versions and edu-
cation and dissemination activities.
ERN ReCONNET survey on CPGs knowledge and awareness in
rare and complex connective tissue disorder patients,
caregivers and family members
Four hundred and ninety-three anonymous responses
were received from patients, caregivers and family mem-
bers. The majority of respondents were suffering or taking
care of patients with SLE (51%), SSc (19%) and SS (16%).
The other diseases were represented as shown in table 2
and it is important to mention that patients’ organisations
exist only for some rCTDs in Europe; therefore, it is more
difficult to reach the rarest rCTDs communities (such as
IgG4). The question ‘What condition/disease do you live
with?’ was specifically designed to enable the respondents
to select more than one disease, in order to include even-
tual comorbidities. Most respondents were aware of the
purpose of CPGs and how they are developed. However,
only 62% of responders were aware of the existence of
CPGs for their disease and 61% had actually read CPGs
produced for their disease. Being aware of the CPGs devel-
oped for their diseasemade patients feelmore empowered
in the healthcare decisions (93%). Moreover, 95% of the
respondents thought that the creation of a patient-friendly
version of CPGs would be useful, especially considering
that CPGs are generally developed in a complex medical
language and therefore not accessible to patients, care-
givers and family members. The creation of empowering
tools was perceived to have a high impact, in particular,
while discussing treatment options and on the general
management of the disease.
The development of patients’ lifestyle guidelines has
collected great interest in 95% of the respondents.
Many comments suggested that patients’ lifestyle guide-
lines should be included in the CPGs to inform both
patients and clinicians on how to better cope with the
disease and on practical tips for daily life. Suggestions of
topics to be included in the patients’ lifestyle guidelines
are guidance for caregivers, recommendations on nutri-
tion and sport, how tomaintain a good quality life, how to
deal with pain and side effects, and practical everyday do’s
and don’ts.
In addition, many comments reported the need for
CPGs to be fully applicable in clinical practice. This is
perceived as achievable only if each CPGs are subject to
local adaptations in each European country. According to
the respondents, the local adaptations would enable clin-
icians to better apply those guidelines in their own country
and improve the quality of care provided to their patients.
CPGs were also perceived as a potential tool to harmo-
nise the clinical approach to the management of rCTDs
and to provide all patients with a uniformed access to
medicinal products and therapeutic interventions in all
European countries.
It is also important to mention that the majority of
respondents recur to healthcare professionals both for
healthcare information and for CPGs. On the other hand,
patients’ organisations and internet/social media are also
used while looking for healthcare information. Different
comments have, in fact, highlighted the difficulty to
RMD Open
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Table 1 Results of the ERNReCONNET survey on clinical practice guidelines adherence in rare and complex connective tissue
disorders: the perspective of healthcare professionals
ERN-ReCONNET survey on the use of clinical practice guidelines for HCPs
Instructions
The survey should take less than 10 minutes, and your responses are completely anonymous.
You can only take the survey once and all questions are required.
The survey is designed to be compled by experts of the following diseases:
We really appreciate your input!
► Antiphospholipid syndrome (APS)
► Ehlers-Danlos syndrome (EDS)
► Idiopathic inflammatory myopathies (IIM)
► IgG4-related disease (IgG4)
► Mixed connective tissue diseases (MCTD)
► Relapsing polychondritis (RP)
► Sjögren’s syndrome (SS)
► Systemic lupus erythematosus (SLE)
► Systemic sclerosis (SS)
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Please select the option that best suits your healthcare provider (HCP) %
General hospital 3.6
University hospital 91.1
Private hospital/healthcare service 1.8
Academic unit affiliated with general
hospital
1.8
Mix of general and university hospital 1.8
What is the volume of your centre? (the average number of rCTDs patients seen per year) %




More than 450 yearly 76.8





















Using well-constructed CPGs will improve patient care







CPGs would not improve the care I give to patients
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I find it helpful to apply CPGs in clinical practice







Existing CPG in my area of expertise are very few or lacking







Existing CPG in my area of expertise are well constructed and valid







How often do you use CPG when assessing patients? %
Never 1.8
Less than once a week 16.1
More than once a week 37.5
Always 44.6












Do you experience any difficulties/barriers to the application of CPG in your HCP? %
Yes 62.5
No 37.5
If yes, please indicate which difficulties/barriers you experience to the application of clinical practice guidelines in your
healthcare provider (more than one option possible)
%
Procedures and drug reimbursement 57.1
Time limit 48.6
Local legislative restrictions 34.3
Awareness/knowledge 20.0
Poor dissemination of guidelines 17.0
Do you have any proposal to increase the adherence to the clinical practice guidelines? (open question)
CPGs, clinical practice guidelines; rCTDs, rare and complex connective tissue and musculoskeletal diseases.
Connective tissue diseases
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Table 2 Results of the ERN ReCONNET survey on clinical practice guidelines knowledge and awareness in rare and complex
connective tissue disorders: patients, families and caregivers
ERNReCONNET survey on clinical practice guidelines knowledge and awareness in rare and complex connective tissue
disorder patients, families and caregivers
Introduction
The European Reference Network for rare and complex connective tissue and musculoskeletal diseases (ERN
ReCONNET) is a virtual network involving 26 centres of expertise across Europe that aims at developing
a comprehensive and harmonised approach to rare and complex autoimmune and hereditary connective and
musculoskeletal diseases (rCTDs).
The ERN ReCONNET is conducting a series of surveys to investigate how much patients, families and caregivers know
about clinical practice guidelines on rare and complex autoimmune and hereditary connective and musculoskeletal
diseases in Europe.
In the next questions, we are going to ask you an honest opinion on clinical practice guidelines. Please do notworry if you
do not understand certain questions or terms used, that is exactly what we are investigating in, it is really important that
your answers are sincere and genuine.
Instructions
The survey should only take less than 10minutes, and your responses are completely anonymous. You can only take the
survey once and all questions are required, please make sure you donot complete the questionnaire twice.
The survey is designed to be completed by patients affected, or by family member and caregivers that live/take care of
a patient affected by one or more of the following diseases:
Pleasenote that this surveyhas beendeveloped for patients, caregiver and familymemberswho live in EUcountries (Austria,
Belgium, Bulgaria, Croatia, Cyprus, CzechRepublic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland,
Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden,
United Kingdom) and Norway.
In case you are not living in one of the countries listed above, we kindly ask you not to answer the survey. Please note also
that the results of this survey may be used in a brief scientific report/abstract to conferences.
If you have any questions about the survey, or about the ERNReCONNET, please email us: ern.reconnet@ao-pisa.toscana.it
We really appreciate your input!
► Antiphospholipid syndrome (APS)
► Ehlers-Danlos syndrome (all except vEDS)
► Idiopathic inflammatory myopathies (including PM and/or DM)
► IgG4-related disease
► Mixed connective tissue diseases (MCTD)
► Relapsing polychondritis (RP)
► Sjögren’s syndrome
► Systemic lupus erythematosus (lupus/SLE)
► Systemic sclerosis (scleroderma, SS)





How old are you? %





Over 65 years 7.6
What is the highest level of school that you have finished? %
Below high school diploma 9.5
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Are you involved in or a member of any patients' organisation/charity? %
Yes 52.5
No 47.5
Do you know the purpose of clinical practice guidelines? %
Yes 51.7
No 48.3
Do you know how a clinical practice guideline is developed? %
Yes 71.3
No 28.7
Are you aware of any clinical practice guideline developed for your disease? %
Yes 38.2
No 61.8
Have you ever read a clinical practice guideline for your disease? %
Yes 39.5
No 60.5
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identify reliable sources of information, especially on the
internet.
DISCUSSION
The results of these surveys provide a first picture of the
level of awareness as well as a first overview of the level of
adherence to CPGs in rare and complexmusculoskeletal
and connective tissue diseases. Considering the critical
impact that guidelines have in the care provided to
patients, it is crucial that a network of expertise on rare
diseases takes a snapshot of what clinicians and patients
think about CPGs. The main message from the HCPs is
that using well-constructed CPGs surely improves
patient care. Well-constructed and valid CPGs exist for
some rCTDs, but others have very few or no CPGs avail-
able, and in fact, this was also reflected in the variability
of the responses. A large part of the enquired HCPs uses
CPGs in routine clinical practice; however, some diffi-





What do you expect from a clinical practice guideline? (open question)
What do you think clinical practice guidelines are developed for? (open question)




Friends and family 8.5
Other 6.0
Do you perceive clinical practice guidelines as something positive or negative? %
Positive 82.7
Negative 0.4
Not sure/donot know 16.9














In a few words, what kind of content would you like to see in the patient-friendly version of the clinical practice guideline?
(open question)
In your opinion, would you feel more empowered in the healthcare decisions if you were properly aware of the clinical





Who would you like to receive information on clinical practice guidelines from?* %
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by local legislative restrictions and time constraints during
the assessment of patients. Many proposals have been sug-
gested to implement the application of CPGs, mainly
related to (i) having easier and more practical versions of
existing CPGs (such as phone and/or computer applica-
tions or an online platform), (ii) increasing knowledge
and education for both patients and professionals on
CPGs, (iii) havingmore dedicated time during the routine
clinical assessment and (iv) having government support
and reduce any local legislative restrictions.
The voices of patients, family members and caregivers
underlined that CPGs should be more widely dissemi-
nated and adapted to the different health systems in
Europe in order to improve the level of care provided to
patients. CPGs are generally perceived positively, but it is
evident that more effort should be dedicated to the inclu-
sion of patients in the development of CPGs. The expec-
tations of respondents on CPGs were focused on the great
benefit that CPGs scan induce on the management of
diseases, especially if the patient is affected by a rare dis-
ease. Respondents also emphasised that patient-friendly
versions of CPGs and patients’ lifestyle guidelines could
play a relevant role in the process of empowering patients
in themanagement of their disease and to support shared
decision with healthcare professionals. The results
obtained in this survey will enable ERN ReCONNET to
plan initiatives related to patients’ empowerment and
CPGs, such as the creation of patient-friendly version of
CPGs and patients’ lifestyle guidelines.
Since ERN ReCONNET aims at improving the level
of adherence to CPGs across European HCPs, by pro-
viding practical tools and training to healthcare pro-
fessionals, many of the initiatives emerging from this
survey are being realised under the scope of the ERN
ReCONNET, following the suggestions, expectations
and points of view of the member HCPs and ePAGs.
The ERN ReCONNET has already reviewed the land-
scape of the existing CPGs in rCTDs10–19 and the
existence of partially sufficient CPGs for some rCTDs
was highlighted, while demonstrating the absence of
evidence-based CPGs for other rCTDs.10–19 Among the
different unmet needs on CPGs, the results raised the
issue that more attention should be devoted to the
assessment of CPGs adherence in routine clinical prac-
tice. In accordance, the ERN ReCONNET aims at
identifying strategies to improve the dissemination
and implementation of CPGs throughout Europe.
Other activities are also ongoing under the scope of
the ERN ReCONNET, both to produce the evidence
needed to create new CPGs, and to adapt existing
CPGs to the different geographical and cultural Eur-
opean contexts and to fulfil the unmet needs and gaps
emerged from the survey.
CONCLUSIONS
Well-constructed CPGs improve patient care, but some
difficulties and barriers still exist in their implementation
in daily clinical activities. Thanks to the engagement of
the most relevant stakeholders involved in rCTDs, the
ERN ReCONNET is promoting practical actions for the
local adaptation of CPGs across Europe, improving their
routine clinical use and contributing to the increase of
the awareness on CPG across rCTDs patients, familymem-
bers and caregivers.
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